Stockreport

SELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Pl...

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Final data from Phase 2b clinical trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) were previously presented at the European Society for Med [Read more]